Hostname: page-component-7b7567c8c-tnkh4 Total loading time: 0 Render date: 2026-11-18T23:00:03.197Z Has data issue: false hasContentIssue false

PL03-01 - Recent developments in the treatment of schizophrenia

Published online by Cambridge University Press:  17 April 2020

C. Höschl*
Affiliation:
Prague Psychiatric Center and 3rd Faculty of Medicine, Charles University, Prague, Czech Republic1st Department of Psychiatry, Medical Faculty, University of Pavel Josef Safarik, Kosice, Slovak Republic

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the 'Save PDF' action button.

The classical antipsychotic drugs exert primarily antidopaminergic properties, which are responsible also for their side-effects such as hyperprolactinemia and extrapyramidal syndrome. Nevertheless, psychotogenic pathways in the brain involve several different mechanisms, which could serve as targets of antipsychotic modalities, e.g., facilitation of glutamatergic and cholinergic neurotransmission, blockade of serotonin 5-HT2 receptors, expression of BDNF and bcl2, inhibition of GSK-3β phosphorylation and thus apoptosis etc.[1] Recent naturalistic trials brought updated experience with regard to efficacy, effectiveness and side-effect profile of antipsychotics and the comparison of antipsychotics of the first and second generation. In addition, recent developments in the treatment of schizophrenia involved also psychoeducation[2] and so called ITAREPS (Information Technology Assisted Relapse Prevention in Schizophrenia)[3], which improve adherence to treatment and therefore decrease significantly the relapse rate.

Submit a response

Comments

No Comments have been published for this article.